Regeneron Pharmaceuticals Inc (REGN)vsVerizon Communications Inc (VZ)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
VZ
Verizon Communications Inc
$50.37
-1.06%
COMMUNICATION SERVICES · Cap: $214.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Verizon Communications Inc generates 863% more annual revenue ($138.19B vs $14.34B). REGN leads profitability with a 31.4% profit margin vs 12.4%. VZ appears more attractively valued with a PEG of 1.23. VZ earns a higher WallStSmart Score of 62/100 (C+).
REGN
Buy58
out of 100
Grade: C
VZ
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Margin of Safety
-82.4%
Fair Value
$27.61
Current Price
$50.37
$22.76 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Mega-cap, among the largest globally
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 21.0%
Generating 4.4B in free cash flow
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
2.0% revenue growth
Weak financial health signals
Earnings declined 53.3%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : VZ
The strongest argument for VZ centers on Market Cap, P/E Ratio, Price/Book. PEG of 1.23 suggests the stock is reasonably priced for its growth.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : VZ
The primary concerns for VZ are Revenue Growth, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
REGN carries more volatility with a beta of 0.40 — expect wider price swings.
REGN is growing revenue faster at 2.5% — sustainability is the question.
VZ generates stronger free cash flow (4.4B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VZ scores higher overall (62/100 vs 58/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Verizon Communications Inc
COMMUNICATION SERVICES · TELECOM SERVICES · USA
Verizon Communications Inc. is an American multinational telecommunications conglomerate and a corporate component of the Dow Jones Industrial Average. The company is headquartered at 1095 Avenue of the Americas in Midtown Manhattan, New York City, but is incorporated in Delaware.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?